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remains the gold standard for assessing suitability for trans-
plant. 
Procurement personnel must always consider the possibility 
of litigation whenever potentially diseased or defective organs 
are to be transplanted. Ordinary negligence liability may result 
if the disease or defect is discoverable with reasonable efforts 
using standard medical practices. Generally, the medical his-
tory is reviewed to rule out vascular disease, infection, or cancer, 
but further testing (e.g., biochemical, biopsy, autopsy, slit lamp 
exams of corneas, or coronary angiography in patients over 40) 
may be required as standard practice in some locales (21). 
Victims of cyanide poisoning have previously been described 
as suitable kidney (19) and corneal transplant donors, provided 
the corneoscleral tissue is rinsed thoroughly and maintained in 
a tissue-storage medium containing glucose (20). To our knowl-
edge, however, this is the first report of successful multiple 
organ donation from a victim of cyanide poisoning. In this case, 
the lack of histological or biochemical evidence of irreversible 
cardiac, hepatic, or renal damage provided the basis for pro-
ceeding with multiple-organ transplantation over the objections 
of several surgeons. 
In summary, we stress that careful donor evaluation and 
testing should be undertaken before excluding poisoned pa-
tients as suitable donor candidates. In the absence of transmis-
sible disease and significant end-organ damage, mere presence 
or clinical effect of a toxicant should not automatically result 
in donor exclusion. Cyanide poisoning is only an example, and 
a rare one at that, of how the donor pool may be safely 
expanded. Brain death associated with exposure to carbon 
monoxide, hydrogen sulfide, azide, or oxidizing agents (causing 
methemoglobinemia) may also warrant evaluation for organ 
procurement. The nature and extent of testing required to 
exclude a poisoning victim will continue to evolve and will 
increasingly depend on what is known about mechanisms of 
cell injury initiated by a particular agent. 
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PARVOVIRUS B19 INFECTION CAUSING PURE RED CELL APLASIA IN A RECIPIENT OF PEDIATRIC 
DONOR KIDNEYS1 
Parvovirus B19, a recently discovered single-stranded DNA 
virus, is a known cause of chronic anemia in immunocompro-
1 This work was supported in part by grants from the Iowa City 
Veterans Affairs Research Fund (to S.J.N.). 
mised patients. This virus has been identified as the etiologic 
agent of the common childhood mild febrile exanthem ery-
thema infectiosum, or "fifth disease", as well as a chronic 
arthralgia in children and adults that is symptomatically simi-
lar to rheumatoid arthritis. At least one fatality from acute 
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myocarditis in a one-year-old child has been reported (1). 
Transient aplastic anemia has been reported in infected pa-
tients with congenital hemolytic anemia such as sickle cell 
disease (2), whereas chronic anemia affects immunocompro-
mised hosts with acquired immunodeficiency syndrome (3) and 
acute lymphocytic leukemia (4,5), and it has been reported in 
a 14 year-old girl following bone marrow transplantation (6). 
Only one previous report of parvovirus B19-producing anemia 
in a solid-organ transplant, that of a cadaveric renal transplant 
recipient receiving cyclosporine, appears in the literature (7). 
We report the case of a pediatric en bloc renal transplant 
recipient on FK506 with pure red cell aplasia and peripheral 
pancytopenia caused by parvovirus B19 that were responsive 
to commercial immunoglobulin administration. 
The patient was a 62 year-old man with diabetic and hyper-
tensive nephropathies and a history of gout, who underwent 
cadaveric renal transplantation using pediatric-donor kidneys 
in an en bloc fashion in February, 1990. At the time of trans-
plant, the recipient's serologic titers were negative for hepatitis 
B surface antigen, anti-hepatitis B antibody, anticytomegalo-
virus IgM, and anti-human immunodeficiency virus antibody, 
while titers were positive for anticytomegalovirus IgG at 1:69, 
and for antihepatitis A IgG by ELISA. The donor was a 16-
month-old girl who died of suspected cardiac arrest secondary 
to anoxia. She exhibited f1u-like symptoms approximately 48 
hr prior to the arrest. Donor serologic titers were negative for 
anti-cytomegalovirus, hepatitis, and human immunodeficiency 
virus antibodies. Parvovirus titers were not performed on donor 
or recipient sera, as they are not included in routine pretrans-
plant serologic testing_ The recipient was discharged 17 days 
posttransplant with a creatinine of 1.5 mg/dl and a hematocrit 
of 33.1 % on an immunosuppressive regimen of FK506 (0.1 mg/ 
kg b.i.d.) and prednisone (10 mg q.d.). He remained well until 
readmission one year posttransplant for an exacerbation of 
gouty arthritis affecting multiple joints, confirmed by f1uid 
aspiration and treated by steroid injections and colchicine. At 
the time of admission, the patient was noted to be pancytopenic. 
Total WBC count was 1700/mm", hematocrit 22.7%, platelet 
count 52,000, and reticulocyte count 0.1 %, with normal red cell 
indices. Rone marrow aspiration and biopsy at that time re-
vealed markedly decreased erythroid maturation with normal 
myeloid series and megakaryocytes, and increased iron stores 
(Fig. 1A). No viral inclusions were present. The serum anticy-
tomegalovirus IgG titer was positive at 1:106 and the IgM titer 
was equivocal at 1:15. However, urine, throat swab, and buffy 
coat CMV cultures and the early antigen assay remained neg-
ative. Colchicine and prophylactic trimethoprim/sulfamethox-
azole were discontinued as they were thought to be likely causes 
of the patient's erythroid hypoplasia. His leukopenia and 
thrombocytopenia improved, and, following transfusion, the 
patient's hematocrit stabilized at 27.7%. During the subsequent 
month, the patient received ten outpatient transfusions of 
packed red blood cells. He was readmitted one month after 
discharge with chest pain, and subsequently a myocardial in-
farction was excluded by enzyme and EKG criteria. At this 
second admission, his hematocrit was 21.6%, his total WBC 
count was 1700/mm'\ his platelet count was 111,000, and his 
reticulocyte count was 0.1 %. A peripheral blood smear revealed 
moderate microcytosis with rare anisocytosis and hypochromia. 
The serum erythropoietin level was elevated at 2820 mU/ml 
(normal 4-26). His chest pain resolved completely after trans-
fusion of two units of packed red blood cells. Repeat cytomeg-
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FIGURE 1. Bone Marrow Morphology. (A) Bone marrow core biopsy 
on previous admission demonstrating erythroid hypoplasia. Myeloid 
cells and megakaryocytes are present. Intranuclear inclusions are not 
seen (H&E; X400). (B) Giant pronormohlast present in the marrow 
aspirate on second admission (Wright-Giemsa; xlOOOl. (e) Bone mar-
row core biopsy on second admission illustrating numerous intranuclear 
inclusions (arrowheads) suggestive of viral infection. Infected cells are 
most likely red cell series precursors (H&E; X400). 
alovirus cultures and early antigen detection were negative. 
Antiparvovirus IgG was detected by western blot analysis of 
the patient's serum (Specialty Laboratories, Los Angeles, 
CAl-however, antiparvovirus IgM was undetectable. Repeat 
bone marrow aspiration and biopsy revealed essentially com-
plete erythroid aplasia (Fig. lC) except for rare giant pronor-
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FIGURE 2. Resolution of anemia following a course of i.v. pooled 
immunoglobulin. Hematocrit levels are indicated by closed squares, 
and absolute reticulocyte counts by closed triangles. Arrows indicate 
transfusion of packed erythrocytes. 
mob lasts (Fig. IB). Numerous eosinophilic intranuclear inclu-
sions were noted in marrow cells (Fig. IC, arrows) suggestive 
of viral infection. The presence of parvovirus B19 DNA was 
detected in the patient's serum by polymerase chain reaction 
(PCR), screening by dot-blot DNA hybridization, and finally 
by Southern blot analysis (University of Iowa, S.J.N.). The 
patient was treated with a ten-day course of an intravenous 
commercial pooled human immunoglobulin preparation with 
subsequent elevation of his reticulocyte count and resolution 
of the anemia (Fig. 2). He was discharged home seven days 
after completion of immunoglobulin therapy in good condition. 
Hematocrit rose to 30.3 and 37.9% at the time of discharge and 
twelve days later, respectively. Four months later, the patient's 
hematocrit slowly drifted down to 29.9%. Repeat bone marrow 
biopsy showed no evidence of viral infection. While on oral 
iron therapy, his hematocrit stabilized at 36.1% two weeks 
later, and remains at 42.1% one year after immunoglobulin 
therapy. 
Bone marrow biopsy specimens obtained from the patient 
two months prior to treatment, one week prior to treatment, 
and four months after treatment were removed from paraffin 
blocks under sterile conditions for PCR, dot-blot, and Southern 
Blot analysis. Parvovirus B19 DNA was detected by Southern 
analysis of PCR product from both bone marrow specimens 
obtained before immunoglobulin therapy, but it was not de-
tected in the posttreatment specimen. 
Parvovirus B19 disease is now a recognized cause of aplastic 
crisis and anemia in patients who are immunocompromised by 
leukemia, hemolytic anemia, and acquired immunodeficiem;:y 
syndrome. However, few cases of such infections have been 
reported in solid-organ transplant recipients. The shortage of 
available kidneys for transplantation has prompted many 
transplant centers to search for means of expanding the donor 
pool. At our institution we have utilized en bloc transplantation 
of pediatric cadaver kidney grafts for adult recipients. This 
technique uses both donor kidneys with donor aorta and vena 
cava intact for anastomosis to recipient iliac vessels. Periaortic 
and pericaval lymphatic tissue is carefully removed during 
preparation of the grafts for transplant. We report the case of 
a pediatric-donor renal transplant recipient who had pure red 
cell aplasia secondary to parvovirus B19 infection one year 
after transplantation, confirmed by PCR and Southern analy-
sis. Serology demonstrated the lack of an IgM response, a 
finding that is not uncommon in immunosuppressed patients 
infected with this virus (8, 9). 
In the case reported here, the infant donor exhibited a viral 
prodrome prior to sudden death, and, since at least one case of 
death from myocarditis caused by parvovirus in an infant has 
been reported (1), this case raises the question of whether 
parvovirus BI9 was transmitted from donor to recipient via the 
allograft. We retrieved autopsy specimens of myocardium and 
bone marrow from the infant donor in this case, both of which 
were tested by PCR and Southern-blot hybridization and found 
to be negative for parvovirus DNA. These tests do not, however, 
completely rule out the possibility of the presence of the virus 
in donor tissues. Further investigation into the prevalence of 
parvovirus Bl9 disease in transplant patients is warranted, as 
this infection may prove to be a common cause of anemia and 
aplastic crisis in the solid-organ transplant recipient. 
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RAPID ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA mRNA EXPRESSION DURING VENOOCCLUSIVE 
DISEASE OF THE LIVER AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION! 
Venoocclusive disease (VOD)* of the liver is a life-threaten-
ing bone marrow transplantation-related complication that 
may occur secondary to high doses of chemotherapy and radia-
tion. VOD of the liver results from fibrous obliteration of the 
terminal hepatic venules, and involves jaundice, hepatomegaly, 
weight gain, and ascites (1,2). The overall incidence of VOD 
after bone marrow transplantation ranges from 10 to 30%, with 
a mortality rate over 40%. The incidence of VOD varies ac-
cording to the conditioning regimen; the incidence of VOD in 
patients administered cyclophosphamide (Cy) plus total-body 
irradiation (CyTBI) and busulfan (Bu) (4 mg/kg for 4 days) 
plus Cy (50 mg/kg for 4 days) (BuCy4) was 21-24% (3, 4), 
compared with 9% with BuCy2 (Cy 60 mg/kg for 2 days) (5). 
The pathogenesis is considered to be secondary to endothelial 
damage of the terminal hepatic venules, followed by activation 
of the coagulation cascade. More recently, it has been suggested 
that the dysregulation of cytokines such as tumor necrosis 
factor-alpha is implicated in transplant-related complications. 
It is also reported that serum TNF-alpha is increased prior to 
transplant-related complication such as acute graft-versus-host 
disease (aGVHD), interstitial pneumonitis (IP) and VOD (6, 
7). 
In two patients (one with chronic myelogenous leukemia, a 
30 year-old man [case 1] and one with acute lymphoblastic 
leukemia L2, a 17 -years-old boy [case 2]) jaundice, hepatomeg-
aly, right upper abdominal pain, weight gain, ascites, and 
hepatic coma developed after allogeneic BMT using BuCy2 as 
a conditioning regimen and cyclosporine and methotrexate as 
immunosupressants, respectively. Ultrasonographic studies of 
the abdomen revealed ascites, thickening of the gallbladder 
wall, and a failure to visualize the major hepatic veins. The 
diagnosis of VOD of the liver was confirmed from these clinical 
features. Both patients were treated with pulse therapy with 
methylprednisolone, continuous infusion of heparin as an an-
ticoagulant, and prostaglandin El as a vasodilator. After inten-
sive therapy, liver function of the patient with CML improved, 
ascites diminished within 10 days, and jaundice resolved within 
30 days, and the patient was alive more than four months after 
transplantation with no acute GVHD. On the other hand, 
although the liver function of the patient with ALL improved 
temporarily, it deteriorated from day 60 and the patient died 
of hepatic failure. Localized skin eruption of acute G VHD grade 
1 was present from day 46 (Fig. 1). Autopsy of this patient 
revealed the typical pathological features of VOD, with fibrous 
obliteration of the terminal hepatic venules. 
1 This work was supported by Grants-in-Aid from the Ministry of 
Education, Science and Culture, Japan. 
* Abbreviations: Bu, busulfan; Cy, cyclophosphamide; PCR, polym-
erase chain reaction; VOD, venoocclusive disease. 
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In the present study, we investigated the expression of TNF -
alpha mRNA and IL-2 mRNA in peripheral mononuclear cells 
using the semiquantitative polymerase chain reaction (PCR) 
(8) to analyze the interaction of cytokines and VOD. The total 
RNA (5 J.Lg) prepared from peripheral mononuclear cells sepa-
rated by centrifugation with Ficoll-Hypaque gradient was re-
verse-transcripted by 600 U murine Moloney leukemia virus 
reverse transcriptase (BRL) with 150 pmol of random hexamer, 
and V20 th of the resulting cD N A was used for PCR. The primers 
(IL-2A 5'CAACTCCTGTCTTGCATTGCACTA3', IL-2B 
5'TGTTGAGATGATGCTTTGACAAAA3' [9], TNF-alpha A 
5'AGTGACAAGCCTGTAGCCCATGTT3', TNF-alpha B 
5' AGACTCGGCAAAGTCGAGATAGTC3' [10], beta-actin A 
5'TTCGAGCAAGAGATGGCCACGGTC3', beta-actin B 
5' ATACTCCTGCTTGCTGATCCACAT3' [11]) were synthe-
sized on a 380B DNA synthesizer (Applied Biosystems). The 
primer sequences were chosen from separate exons of the genes. 
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FIGURE 1. The clinical course of patients who developed venoocclu-
sive disease of the liver. 
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